OBJECTIVES: Surgical techniques including sentinel lymph node biopsy (SLNB) and 4-node sampling (4-NS) are currently used for axillary nodal assessment of early breast cancer (EBC) in the UK. Such procedures are associated with adverse effects, (AEs), in particular scarring, pain, general anaesthesia and occasional lymphoedema which may impact on long term quality of life. Magnetic resonance imaging (MRI) is a non-invasive technique offering the potential to avoid such AEs. A range of MRI techniques, including USPIO (ultrasmall superparamagnetic iron oxide contrast agent)-enhanced and gadolinium-enhanced MRI exist, however diagnostic accuracy of these techniques may be lower than for surgical techniques. An economic evaluation was undertaken to compare MRI with surgical techniques for assessment of axillary lymph node metastases in patients with EBC. METHODS:
OBJECTIVES:
To assess the cost-effectiveness of cardiac resynchronisation therapy (CRT) both with CRT-P (biventricular pacemaker only) and CRT-D (biventricular pacemaker with defibrillator) in patients with New York Heart Association (NYHA) functional class III/IV from a Belgian health care payer perspective. METHODS: A lifetime Markov model was designed to calculate the cost-utility of both interventions. In the reference case, the treatment effect is based on the COMPANION trial. Costs are based on real-world data. Pharmacoeconomic guidelines were applied, including probabilistic modelling and sensitivity analyses. RESULTS: Compared with optimal medical treatment, on average 1.31 quality-adjusted life-years (QALY) are gained with CRT-P at an additional cost of €14,700, resulting in an incremental cost-effectiveness ratio (ICER) of about €11,200/QALY. As compared to CRT-P, CRT-D treatment adds on average an additional 0.55 QALYs at an extra cost of €30,900 resulting in an ICER of €57,000/QALY. This result was very sensitive to the incremental clinical benefit of the defibrillator function on top of CRT. CONCLUSIONS: Based on efficiency arguments, CRT-P can be recommended for NYHA class III and IV patients if there is a willingness to pay more than €11,000/ QALY. Even though CRT-D may offer a survival benefit over CRT-P, the incremental clinical benefit appears to be too marginal to warrant a three times higher device price for CRT-D. Further clinical research should focus on the added value of CRT-D over CRT-P.
PMD51 COST SAVINGS AND IMPROVED UTILITY THROUGH THE USE OF FLORBETABEN BETA-AMYLOID PET IMAGING IN DEMENTIA DIAGNOSIS
Pastätter R 1 , Uhl-hochgräber K 2 , Blankenburg M 2 1 Karolinska Institute, Stockholm, Sweden, 2 Bayer HealthCare Pharmaceuticals, Berlin, Germany OBJECTIVES: Early diagnosis of Alzheimer's disease may allow for early appropriate treatment, delayed symptom aggravation, delayed nursing home placement, and reduced care costs. The use of Amyloid-specific Positron Emission Tomography (PET) scanning might complement routine clinical diagnostic procedures and lead to earlier and more accurate differential diagnosis than presently possible. The aim of this study is to estimate cost-effectiveness of Florbetaben PET imaging.
METHODS:
A decision-analytic model using Markov cohorts to simulate Alzheimer's disease (AD) management compares, from a societal perspective, three strategies after routine clinical assessment: 1) use of Florbetaben PET to direct treatment decisions; 2) "treat all" approach; 3) "wait and see" approach. RESULTS: Florbetaben PET appears to be cost-effective and strictly dominant: both comparator strategies result in higher long-term costs at lower health outcomes. Values of incremental costs saved (US$2340 -without considering cost of Florbetaben tracer) and health outcomes gained (0.028 QALYs) to the nearest comparator strategy are small. However, the results prove to be robust in sensitivity analyses. CONCLUSIONS: Although Florbetaben PET imaging has significant upfront costs, identifying and treating patients with AD early and correctly results in overall cost savings and QALYs gained. This analysis may underestimate the true benefit of Florbetaben PET imaging because the value of knowing early about the underlying pathology from the perspective of patients and caregivers is not implemented in the model -apart from medical and economic value, even emotional aspects and the opportunity for future planning should be considered. This could be subject of further research.
PMD52 WORKLOAD IN GERMAN HOSPITALS CAUSED BY ROUTINE FOLLOW-UP SERVICES FOR CARDIAC IMPLANTABLE ELECTRICAL DEVICES (CIED)
Smala A 1 , Vogtmann T 2 1 Biotronik SE & Co KG, Global Reimbursement and Health Economics, Berlin, Germany, 2 Kardiologische Gemeinschaftspraxis "Am Park Sanssouci", Potsdam, Germany OBJECTIVES: Regular follow-up (FU) of CIED patients is mandatory to monitor device functionality and disease status. Demand for this highly specialised service increases continuously. However, most calendar based visits do not need further action and could safely be replaced by remote monitoring. This model aims 1) to quantify hospital workload associated with calendar based FU between 2011 and 2015, and 2) to identify opportunity costs if monitoring services would be performed remotely. METHODS: The estimated number of prevalent CIED patients in Germany was combined with recently published data on healthcare personnel resource burden related to FU. Opportunity costs were identified considering 2011 DRG payments for frequent cardiology procedures. RESULTS: Assuming in-office FU twice annually for pacemaker patients, and four times annually for implantable cardioverter defibrillator or cardiac resynchronisation therapy patients, hospitals will have to provide about 2.23 mio FU services in 2015, to about 856,000 patients. These services will bind about 411,000 physician hours, 392,000 nurse hours and 280,000 technician hours, at total costs of EURO 44.8 mio to hospitals. Using remote monitoring to replace all but one in-office FU visit per year could free up to 126,700 physician hours (2015) . In theory, this physician time would allow for about 50'600 bypass surgeries (worth EURO 596 mio), or 84,400 dual-chamber pacemaker implantations (EURO 434 mio), or 63,300 dual chamber ICD implantations (EURO 1.1 billion). Possible cost overestimation due to not considering unscheduled FU visits is explored in scenario analyses. CONCLUSIONS: The ability of BIOTRONIK Home Monitoring to safely replace in-office FU visits has been proven in clinical trials. While continuously monitoring all patients, it is possible to identify patients in need to attend in clinic FU in person. Remote monitoring technologies can support hospitals with focussing their available staff and room capacities and optimise operative income while providing patient care at potentially improved outcomes.
PMD53 PULMONARY VEIN ISOLATION FOR THE TREATMENT OF PAROXYSMAL AF: TIME REDUCTION AND PRODUCTIVITY GAIN WITH "ANATOMICALLY-DESIGNED" CATHETHERS COMPARED TO "POINT BY POINT" CATHETERS
Fagnani F 1 , Coulomb S 1 , Marcaud N 2 , Bouchet M 2 , Bonté J 1 1 Cemka, Bourg la Reine, France, 2 Medtronic France SAS, Boulogne Billancourt, France OBJECTIVES: Electrical Pulmonary Vein (PV) Isolation (PVI) is regarded as effective treatment of Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation (PAF). Traditionally, appropriate circumferential lesions were created point-by-point, using single tip catheters guided by navigation systems, and generally employing radiofrequency (RF) source. "Anatomically-Designed" catheters were introduced recently and are pre-shaped to create the appropriate lesions with a single application on each PV. We hypothesised that the shape of these catheters is associated with reduced procedure times and Operating Room (OR) productivity gains. In this study, catheters employing cryo (Arctic Front, Medtronic) and duty cycled bipolar radiofrequency (PVAC, Medtronic) energy sources were examined. METHODS: Using a chart review approach, 158 procedures were included (85 with "anatomicallydesigned" catheters, 73 "point-by point") across 7 diversified French centres. Selection criteria were used to ensure comparability of procedures. In parallel an economic analysis was performed to estimate the budgetary impact in terms of DRG case-mix for hospitals, resulting from potential increased OR activity. RESULTS: Reduced procedure time was observed in six out of seven participating centres. The difference in median times was 35 minutes (pϭ0.0192). There was significant variability of procedures times depending on hospital status (public or private), the experience of electrophysiologists involved and the annual activity. Based on the DRG casemix produced in the rythmology OR and the current tariffs, the mean revenue for the centre was estimated between 1100€ (private) and, 400 € (public) per hour of total OR time. CONCLUSIONS: Use of "Anatomically-Designed" PVI Catheters has the potential to substantially reduce procedure time and increase procedure capacity of rythmology labs. Shorter procedure times allow better management of OR and treatment of more patients with potential productivity gains to hospitals that may offset the extra cost of the new techniques. 
PMD54 RESOURCE UTILISATION RELATED TO CATHETER-ASSOCIATED URINARY TRACT INFECTIONS IN SWEDISH SPINAL INJURY PATIENTS

OBJECTIVES:
To collect real-life data on costs and resource use, in order to understand the economic burden and treatment patterns of urinary tract infection (UTI) amongst people with spinal injury, who are in need of chronic, intermittent catheterisation. METHODS: We used the CEBRxA database, which combines data from a public claims database for the South-West region of Sweden, comprising around 1.5 million individuals, with national Swedish registers on drug utilisation and mortality. We identified a population of spinal injury patients (ICD-10 S14.0, S24.0, S34.0, and T91.31) who in addition had received a diagnosis of neurogenic bladder (ICD-10 N31*), anytime during the years 2000 to 2009. UTIs were identified through the following ICD-10 codes: N11.0, N30*, N39.0*, N39.X*, N12.-P, and N30.-P. A cost per UTI was calculated through considering UTI-related care contacts that occurred within 14 days from each other (from 2005-07-01 onwards). RESULTS: We identified 295 spinal injury patients, with a mean age at index of 44 years, an average follow-up time of 6 years, and of which 79% were males. For 67% of the population we observed at least one UTI, which resulted in a care contact. Interestingly, a quarter of the population used prophylactic antibiotics (J01XX05), corresponding to an average of 235 DDDs per year, amongst users. A majority of UTIs were handled in primary care, while over 90% of costs were contributed by UTIrelated hospitalisations. The mean cost per UTI was 43,500 SEK, while estimates varied considerably, with costs ranging from an average of 1,800 SEK for UTIs handled in primary care to 177,200 SEK for inpatient care. CONCLUSIONS: In a population of spinal injury patients, costs for catheter-associated urinary tract infections are to a large extent driven by outlier, expensive hospitalisation. There would be a large potential for cost savings if these hospitalisations could be avoided.
PMD55 RESOURCE UTILISATION RELATED TO URINARY TRACT INFECTIONS IN SWEDISH SELF-CATHETERISATION PATIENTS
Löfroth E 1 , Bruce S 1 , Knutsson B 2 , Börstell T 2 , Myrén KJ 1 1 IMS Health, Stockholm, Sweden, 2 AstraTech, Mölndal, Sweden OBJECTIVES: To collect real-life data on costs and resource use, in order to understand the economic burden of urinary tract infection (UTI) amongst a population who has received self-catheterisation training. METHODS: We used the CEBRxA database, which combines data from a public claims database for the South-West region of Sweden, comprising around 1.5 million individuals, with national Swedish registers on drug utilisation and mortality. We identified a population of patients who had received self-catheterisation training anytime between 2006 and 2009(procedure code GB005). UTIs were identified through the following ICD-10 codes: N11.0, N30*, N39.0*, N39.X*, N12.-P, and N30.-P. A cost per UTI was calculated through considering UTI-related care contacts that occurred within 14 days from each other. RESULTS: We identified 989 patients, with a high mean age at index of 65 years, 79% males, and an average follow-up time of 1.5 years. The disease burden of this population was mainly related to the genitourinary system, like retention of urine, benign prostate hyperplasia, cystitis, and neurogenic bladder, although essential hypertonia emerged as the third most common comorbidity. We observed an average frequency of one UTI every two years, while around one-fifth of patients had a yearly UTI-frequency of one or above. A majority of UTIs were handled in primary care, while around 80% of costs were contributed by UTI-related hospitalisations. However, among female patients, inpatient care only contributed to 60% of total costs. The mean cost per UTI was 10,500 SEK, while estimates varied, with average costs ranging from 2,100 SEK in primary care, to 32,000 SEK for inpatient care. CONCLUSIONS: Patients having received self-catheterisation training were on average of higher age and male. UTI-related hospitalisation was a clear driver of costs, although this effect was less pronounced for women. OBJECTIVES: Approximately 880,000 tonsillectomy/adenoidectomy procedures are performed in the US annually. Hemostatic matrix (FLOSEAL) is used for adjunctive hemostasis in a variety of surgeries, but the health economic rationale supporting its application in tonsillectomy and adenoidectomy has yet to be established. A systematic literature review was conducted in order to examine the evidence for hemostatic matrix and to consider its value in reducing the burden of these procedures. METHODS: Applying keywords and inclusion criteria, the PubMed, EMBASE, and Centre for Reviews and Dissemination databases were queried for studies published in English up to March 1, 2011. Reference lists and the American Academy of Otolaryngology-Head and Neck Surgery database were also manually searched. Data on costs, resource utilization, and health outcomes were extracted and summarized. RESULTS: Four prospective, randomized controlled trials provided data on 187 patients treated with hemostatic matrix. In the two studies utilizing crossover design, no patients in the hemostatic matrix groups required electrocautery, whereas 3 of 35 (9%) and 4 of 34 (12%) patients, respectively, required adjunctive hemostatic matrix intraoperatively after failing electrocautery. In all three studies measuring operating room time, use of hemostatic matrix resulted in significantly shorter mean durations (range, 0.93 to 24.6 minutes) compared to electrocautery (range, 9.53 to 32.6 minutes) (all studies, PϽ0.05). Although postoperative bleeding rates did not differ, hemostatic matrix-treated patients in three of four studies reported significant reductions in postoperative pain scores and narcotic consumption compared to electrocautery-treated patients (PϽ0.05). CONCLUSIONS: Published evidence suggests that hemostatic matrix is effective in achieving intraoperative hemostasis during tonsillectomy/adenoidectomy. Given the high volume of procedures, using hemostatic matrix during tonsillectomy and adenoidectomy may be potentially cost saving due to resulting reductions in operating time and postoperative narcotic consumption. Further research may identify patients who are more likely to benefit from hemostatic matrix in this indication.
PMD56 A SYSTEMATIC LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC OUTCOMES ATTRIBUTABLE TO THE USE OF HEMOSTATIC MATRIX DURING TONSILLECTOMY AND ADENOIDECTOMY
PMD57
DATA VISUALIZATION FOR BUSINESS INTELLIGENCE: ASSESSING AN ONLINE TOOL USED FOR BENCHMARKING HOSPITAL PROCEDURE COSTS TO REIMBURSMENT IN CARDIAC CATHETERIZATION AND ELECTOPHYSIOLOGY PROCEDURES
Cload P 1 , Mallow P 2 , Mako J 2 , Gunnarsson C 3 1 GE HealthCare, Chalfont St Giles, UK, 2 s2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3 S2 Statistical Solutions, Inc., Cincinnati, OH, USA OBJECTIVES: Data visualization as a form of business intelligence and knowledge discovery will democratize the use of large scale payer/claims and electronic medical records databases. The goal of this analysis was to assess the feasibility of utilizing Tableau Software™ to create a data visualization tool that would augment data mining and analytic methods for understanding hospital costs and reimbursement patterns in cardiac catheterization and electrophysiology procedures. METHODS: The Premier Perspective ® database was utilized for this analysis. The Premier Perspective ® database houses data from over 600 hospitals and ambulatory surgery centers across the United States. Eligible procedures were those that occurred during the year 2010 with the associated ICD-9 or CPT codes for either cardiac catheterization or electrophysiology procedures. All data were imported into Tableau Software™ and dashboards were created to visualize the data by procedure costs and department costs. Summary statistics of hospital utilization, total costs, components of costs, and hospital charges for both inpatient and outpatient settings are available for exploration in a dynamic manner by each quarter in 2010. Each dashboard is hosted in a secure online environment and fully interactive allowing for dozens of different filters to be applied. RESULTS: For the year 2010 there were 1,104,936 visits of cardiac related procedures With 164,210 unique cardiac catheterization procedures and 22,263 cardiac electrophysiology procedures. Custom developed dashboards show procedures (and associated volumes) by in-and out-patient status, by ICD-9 or CPT code, department, costs and CMS reimbursement levels. This data visualization tool makes it possible to quickly see hospital cost breakdowns on dozens of different dimensions. CONCLUSIONS: Tableau Software™ is a powerful tool to enable the health outcomes researcher to have insights into complex multilevel data. Business intelligence tools developed in this manner enable visual interaction and exploration of data for rapid hypothesis generation and business intelligence.
Medical Device/Diagnostics -Patient-Reported Outcomes & Preference-Based Studies
PMD58 PROVISION AND FINANCING OF MEDICAL AIDS IN THE MANAGEMENT OF RARE DISEASES: THE CASE OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Henschke C Berlin University of Technology, Berlin, Berlin, Germany OBJECTIVES: Patients suffering from ALS have a need for a multitude of medical aids. Existing (bureaucratic) hurdles might create plenty of problems for people with rare diseases. Uncertainty about provision of medical aids and substantial waiting times limit patient's ability to participate in the activities of daily living. This study aims 1) to analyze problems in financing and provision of medical aids; 2) to explore differences in reimbursement decisions of private and social health insurance (SHI); and 3) to explore patient satisfaction according to the type of health insurance. METHODS: First, published and grey literature was used to analyse payment flows and supply chain activities of the various actors involved in the provision and payment of medical aids. Second, a survey of ALS patients (nϭ20) based on semi-standardized questionnaires was conducted . Gathered information included patients' demographic characteristics, information on coverage decisions and problems in the provision of medical aids. Based on patient satisfaction, analysis of variance tests were performed to investigate differences in satisfaction between SHI and privately insured persons. RESULTS: A majority of patients experienced problems in reimbursement decisions, particularly in the case of expensive or individually customized technologies. These reimbursement problems were more common among SHI insured persons. Both SHI insured and privately insured persons complain about long duration processes of individual requests for meeting the cost. Nonetheless, most patients stated that they were satisfied with the actual provision of medical aids, including product and service quality. CONCLUSIONS: Our results suggest that difficulties with medical aids' reimbursement decision processes are a common problem among SHI and private insured ALS patients. Although the patient's insurance type has an impact on these time-consuming process. Consequently, there is a need for an interdisciplinary approach in the provision of medical aids. Case managers might be a solution to overcome these problems.
PMD59 COMPLICATED PARKINSON'S DISEASE: DISCRETE CHOICE ANALYSIS TO ASSESS PATIENTS' PREFERENCES. A PILOT STUDY
Lloyd AJ 1 , Herdman M 2 , Gonzalez P 3 1 Oxford Outcomes, an ICON plc Company, Oxford, Oxon, UK, 2 Insight Consulting & Research, Mataro, Spain, 3 Medtronic Iberia, Madrid, Spain OBJECTIVES: In advanced or complicated Parkinson's disease (CPD), among other treatment alternatives, patients can receive deep brain stimulation (DBS) or continuous duodenal levodopa-carbidopa infusion (CDLCI). This pilot study was designed to understand the preferences of patients who face these treatment choices. METHODS: Treatment attributes were identified based on a literature review, focus groups with patients, caregivers, and interviews with clinicians. A discrete choice experiment survey was developed, reviewed by clinicians and piloted with patients. Patients (potentially considering DBS or CDLCI) in Spain (nϭ30) and the UK (nϭ10) completed the survey . Treatment attributes included surgery type, impact on daily life, medication need, speech difficulties, movement control, dyskinesia, and off-periods. Data were analyzed using a multi-level hierarchical logistic model. RESULTS: Surgery type (DBS electric lead insertion in the brain vs CDLCI intraduodenal tube placement) was the most powerful predictor in the model, with a pref-A254
